| Followers | 1 |
| Posts | 431 |
| Boards Moderated | 0 |
| Alias Born | 12/14/2024 |
Friday, June 20, 2025 2:01:18 PM
Just because it hasn’t been blasted across press releases doesn’t mean it didn’t exist or wasn’t strategically relevant.
Please point to those results, then. They would be very interesting to peruse.
You pretend that a lack of published results means the trial is meaningless.
No, you're right. We should be excited for this trial that never began, the status of which hasn't been updated since 2020.
You mock T cell infiltration as though it is fringe, when in fact it is one of the most critical features of tumor response in checkpoint inhibitor synergy
No, I pointed out that it's not an endpoint used in clinical trials. If you see T cell infiltration but no improvement in clinical outcomes, then you will get nowhere with the oncology community.
If you had, you would know that DCVax L is not competing with checkpoint inhibitors. It is enabling them.
This remains to be seen.
You dismiss pseudoprogression data without understanding its relevance. In glioblastoma
I think maybe you don't know what a P value actually means, either. Again, look at the patient numbers in that KM curve.
The correlation with long term survival is well documented, both in peer reviewed literature and in the DCVax Phase 3 results published in JAMA Oncology.
The JAMA article AND peer-reviewed literature? Wow I didn't know that.
Your entire posture is built on mocking terminology, belittling immune mechanisms, and pretending that sarcasm is a substitute for scientific understanding
You're right. I should just respond with derogatory word salad.
Did you actually read my response? You haven't responded to anything other than my tone, which you seem very upset by.
The word seminal has an actual definition in biomedical science.
It sure does! And that definition is not "deep, thorough."
So does external control arm.
Sure does! Don't know what that pertains to!
So does immune priming
Sure does! Don't know what that pertains to.
You just do not use them because you are not here for clarity. You are here to troll.
If I was here to troll, I wouldn't be posting facts.
DStock gave you a path to learn. You chose to posture.
DStock gave me a path to understanding the mentality of people who have way too much invested in this company, and way too little understanding of the field of oncology.
You came back with snark and no citations.
You guys don't bother reading citations. You don't even read your own.
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
